UK markets closed

Xeris Pharmaceuticals, Inc. (XERS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.7400-0.0200 (-1.14%)
At close: 04:00PM EDT
1.7300 -0.01 (-0.57%)
After hours: 06:56PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
163,914
163,914
110,248
49,590
20,435
Cost of revenue
28,645
28,645
22,634
13,318
9,328
Gross profit
135,269
135,269
87,614
36,272
11,107
Operating expenses
Research development
22,341
22,341
20,966
25,160
20,921
Selling general and administrative
146,095
146,095
137,745
125,718
73,732
Total operating expenses
179,279
179,279
169,554
151,428
94,653
Operating income or loss
-44,010
-44,010
-81,940
-115,156
-83,546
Interest expense
26,609
26,609
14,102
7,180
10,660
Total other income/expenses net
2,364
2,364
-2,620
-702
-9
Income before tax
-63,504
-63,504
-96,084
-122,725
-91,250
Income tax expense
-1,249
-1,249
-1,424
0
-110
Income from continuing operations
-62,255
-62,255
-94,660
-122,725
-91,140
Net income
-62,255
-62,255
-94,660
-122,725
-91,140
Net income available to common shareholders
-62,255
-62,255
-94,660
-122,725
-91,140
Basic EPS
-2.14
-
-0.70
-1.55
-2.14
Diluted EPS
-2.14
-
-0.70
-1.55
-2.14
Basic average shares
42,643
-
135,629
79,027
42,643
Diluted average shares
42,643
-
135,629
79,027
42,643